Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Fructose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fructose SCHEMBL7531716 | 1.00 | CYP2C9 (0.54) | CYP2C9TSHRLMNAPDE4AL3MBTL1 | |
| Fructose SCHEMBL27819910 | 1.00 | CYP2C9 (0.54) | CYP2C9TSHRLMNAPDE4AL3MBTL1 | |
| Fructose SCHEMBL5436569 | 0.98 | CYP2C9 (0.52) | CYP2C9TSHRLMNAPDE4AL3MBTL1 | |
| Fructose SCHEMBL4176977 | 0.98 | LMNA (0.54) | CYP2C9TSHRLMNAPDE4AL3MBTL1 | |
| Fructose SCHEMBL19895680 | 0.95 | CYP2C9 (0.54) | CYP2C9TSHRLMNAPDE4AL3MBTL1 | |
| Fructose SCHEMBL10533309 | 0.95 | CYP2C9 (0.54) | CYP2C9TSHRLMNAPDE4AL3MBTL1 | |
| Fructose SCHEMBL9110450 | 0.95 | CYP2C9 (0.54) | CYP2C9TSHRLMNAPDE4AL3MBTL1 | |
| Fructose SCHEMBL10908351 | 0.95 | CYP2C9 (0.54) | CYP2C9TSHRLMNAPDE4AL3MBTL1 | |
| Tagatose SCHEMBL23827342 | 0.95 | CYP2C9 (0.58) | CYP2C9TSHRLMNAPDE4AL3MBTL1 | |
| Fructose SCHEMBL20898472 | 0.95 | CYP2C9 (0.58) | CYP2C9TSHRLMNAPDE4AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110753755-B | T cell depletion state specific gene expression regulator and application thereof | 丹娜法伯癌症研究院 | 2023-12-29 | — | — | CN | disclosed |
| EP-3291811-B1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-10265314-B2 | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-04-23 | — | — | US | disclosed |
| US-10189856-B2 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | ADVERIO PHARMA GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
| EP-3291811-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | disclosed |
| US-20160346366-A1 | FUSION PROTEINS COMPRISING FACTOR IX FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF | CSL BEHRING LLC | 2016-12-01 | — | — | US | disclosed |
| WO-2016177660-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
| US-20160158233-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | BAYER PHARMA AKTIENGESELl SCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| EP-3024455-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | Bayer Pharma Aktiengesellschaft (DE) | 2016-06-01 | — | — | EP | disclosed |
| US-20030170279-A1 | Emulsion vehicle for poorly soluble drugs | SONUS PHARMACEUTICALS, INC. | 2003-09-11 | — | — | US | disclosed |
| US-20030147959-A1 | Emulsion vehicle for poorly soluble drugs | SONUS PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030104015-A1 | Emulsion vehicle for poorly soluble drugs | SONUS PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030027858-A1 | Emulsion vehicle for poorly soluble drugs | SONUS PHARMACEUTICALS, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6458373-B1 | Emulsion vehicle for poorly soluble drugs | SONUS PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6172085-B1 | CENTRAL NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-0981328-A1 | EMULSION VEHICLE FOR POORLY SOLUBLE DRUGS | SONUS PHARMACEUTICALS, INC. (US) | 2000-03-01 | — | — | EP | disclosed |
| US-5980924-A | IMPREGNATED SHEET WITH AN AQUEOUS COMPOSITION CONTAINING A NONIONIC SURFACTANT AND A POLYHYDRIC ALCOHOL OR GLYCOL ETHER; TO SMEAR AND REMOVE MAKEUP AND SEBUM, LOW IRRITATIVENESS TO THE SKIN | KAO CORPORATION (JP) | 1999-11-09 | — | — | US | disclosed |
| WO-1998030205-A9 | EMULSION VEHICLE FOR POORLY SOLUBLE DRUGS | — | 1998-12-30 | — | — | WO | disclosed |
| WO-1998030205-A1 | EMULSION VEHICLE FOR POORLY SOLUBLE DRUGS | SONUS PHARMACEUTICALS, INC. (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169095-A1 | THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC) | PDE5A, PDE2A, PDE3A | CYP2C9 3448/4885TSHR 4322/4885LMNA 3863/4885 |
| US-20030170279-A1 | Emulsion vehicle for poorly soluble drugs | TTPA, SUCNR1, SDHA | CYP2C9 1332/4885TSHR 2367/4885LMNA 1950/4885 |
| US-20030147959-A1 | Emulsion vehicle for poorly soluble drugs | TTPA, SUCNR1, SDHB | CYP2C9 768/4885TSHR 2684/4885LMNA 2098/4885 |
| US-20030104015-A1 | Emulsion vehicle for poorly soluble drugs | TTPA, SUCNR1, SDHA | CYP2C9 1332/4885TSHR 2367/4885LMNA 1950/4885 |
| US-20160158233-A1 | SGC STIMULATORS OR SGC ACTIVATORS AND PDE5 INHIBITORS IN COMBINATION WITH ADDITIONAL TREATMENT FOR THE THERAPY OF CYSTIC FIBROSIS | PDE5A, PDE3A, GMPS | CYP2C9 4003/4885TSHR 1714/4885LMNA 3358/4885 |
| US-20030027858-A1 | Emulsion vehicle for poorly soluble drugs | TTPA, SUCNR1, SDHA | CYP2C9 1332/4885TSHR 2367/4885LMNA 1950/4885 |
| US-10265314-B2 | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis | PDE5A, GMPS, PDE3A | CYP2C9 4654/4885TSHR 2238/4885LMNA 3213/4885 |
| US-10189856-B2 | Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | PDE5A, PDE3A, PDE2A | CYP2C9 3503/4885TSHR 3172/4885LMNA 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.